法尼甾体X受体
代谢综合征
血脂异常
胆汁酸
腹部肥胖
医学
核受体
平衡
内分泌学
葡萄糖稳态
内科学
生物信息学
糖尿病
胰岛素抵抗
化学
生物
生物化学
转录因子
基因
作者
Bertrand Cariou,Bart Staels
标识
DOI:10.1016/j.tips.2007.03.002
摘要
The metabolic syndrome is an insulin-resistant state that is characterized by a cluster of cardiovascular risk factors, including abdominal obesity, hyperglycemia, elevated blood pressure and combined dyslipidemia. In this review, we discuss the role of the bile-acid-activated farnesoid X receptor (FXR) in the modulation of the metabolic syndrome. Owing to its regulatory actions in lipid and glucose homeostasis, FXR is a potential pharmacological target. Moreover, the observation that FXR also influences endothelial function and atherosclerosis indicates a regulatory role in the cardiovascular complications that are associated with the metabolic syndrome. The pharmacological activation of FXR leads to a complex response that integrates beneficial actions and potentially undesirable side-effects. Thus, the identification of selective FXR modulators (selective bile acid receptor modulators) is required for the development of compounds that can be used to treat the metabolic syndrome.
科研通智能强力驱动
Strongly Powered by AbleSci AI